Real‐world evidence of systemic treatment practices for biliary tract cancer in Japan: Results of a database study
Purpose To describe the real‐world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of biliary infection in Japan. Methods Patients diagnosed with BTC and prescribed systemic therapy between January 2011 and September 2020 were retri...
Saved in:
Published in | Journal of hepato-biliary-pancreatic sciences Vol. 31; no. 7; pp. 468 - 480 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Japan
Wiley Subscription Services, Inc
01.07.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose
To describe the real‐world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of biliary infection in Japan.
Methods
Patients diagnosed with BTC and prescribed systemic therapy between January 2011 and September 2020 were retrieved from the Japanese Medical Data Vision database. The look‐back period was set to 5 years. Patient characteristics, treatment patterns, and biliary infection‐induced treatment interruption were analyzed.
Results
The full analysis set comprised 22 742 patients with a mean age of 71.0 years and 61.6% were male. The most common BTC type was extrahepatic cholangiocarcinoma (44.6%). The three most common first‐line regimens were S‐1 monotherapy (33.0%), gemcitabine+cisplatin (32.5%), and gemcitabine monotherapy (18.7%) over the entire observation period (January 2011–September 2021). Patients who received monotherapies tended to be older. Biliary infection‐induced treatment interruption occurred in 29.5% of patients, with a median time to onset of 64.0 (interquartile range 29.0–145.0) days. The median duration of intravenous antibiotics was 12.0 (interquartile range 4.0–92.0) days.
Conclusions
These results demonstrated potential challenges of BTC in Japanese clinical practice particularly use of multiple regimens, commonly monotherapies, which are not recommended as first‐line treatment, and the management of biliary infections during systemic therapy.
This large‐scale database study provides a comprehensive overview of the systemic therapies for biliary tract cancer and biliary infections in real‐world clinical practice in Japan prior to the immunotherapy era. Ueno and colleagues identified some challenges related to multiple first‐line treatments and the management of biliary infections during systemic therapy. |
---|---|
AbstractList | Purpose
To describe the real‐world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of biliary infection in Japan.
Methods
Patients diagnosed with BTC and prescribed systemic therapy between January 2011 and September 2020 were retrieved from the Japanese Medical Data Vision database. The look‐back period was set to 5 years. Patient characteristics, treatment patterns, and biliary infection‐induced treatment interruption were analyzed.
Results
The full analysis set comprised 22 742 patients with a mean age of 71.0 years and 61.6% were male. The most common BTC type was extrahepatic cholangiocarcinoma (44.6%). The three most common first‐line regimens were S‐1 monotherapy (33.0%), gemcitabine+cisplatin (32.5%), and gemcitabine monotherapy (18.7%) over the entire observation period (January 2011–September 2021). Patients who received monotherapies tended to be older. Biliary infection‐induced treatment interruption occurred in 29.5% of patients, with a median time to onset of 64.0 (interquartile range 29.0–145.0) days. The median duration of intravenous antibiotics was 12.0 (interquartile range 4.0–92.0) days.
Conclusions
These results demonstrated potential challenges of BTC in Japanese clinical practice particularly use of multiple regimens, commonly monotherapies, which are not recommended as first‐line treatment, and the management of biliary infections during systemic therapy.
This large‐scale database study provides a comprehensive overview of the systemic therapies for biliary tract cancer and biliary infections in real‐world clinical practice in Japan prior to the immunotherapy era. Ueno and colleagues identified some challenges related to multiple first‐line treatments and the management of biliary infections during systemic therapy. To describe the real-world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of biliary infection in Japan. Patients diagnosed with BTC and prescribed systemic therapy between January 2011 and September 2020 were retrieved from the Japanese Medical Data Vision database. The look-back period was set to 5 years. Patient characteristics, treatment patterns, and biliary infection-induced treatment interruption were analyzed. The full analysis set comprised 22 742 patients with a mean age of 71.0 years and 61.6% were male. The most common BTC type was extrahepatic cholangiocarcinoma (44.6%). The three most common first-line regimens were S-1 monotherapy (33.0%), gemcitabine+cisplatin (32.5%), and gemcitabine monotherapy (18.7%) over the entire observation period (January 2011-September 2021). Patients who received monotherapies tended to be older. Biliary infection-induced treatment interruption occurred in 29.5% of patients, with a median time to onset of 64.0 (interquartile range 29.0-145.0) days. The median duration of intravenous antibiotics was 12.0 (interquartile range 4.0-92.0) days. These results demonstrated potential challenges of BTC in Japanese clinical practice particularly use of multiple regimens, commonly monotherapies, which are not recommended as first-line treatment, and the management of biliary infections during systemic therapy. To describe the real-world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of biliary infection in Japan.PURPOSETo describe the real-world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of biliary infection in Japan.Patients diagnosed with BTC and prescribed systemic therapy between January 2011 and September 2020 were retrieved from the Japanese Medical Data Vision database. The look-back period was set to 5 years. Patient characteristics, treatment patterns, and biliary infection-induced treatment interruption were analyzed.METHODSPatients diagnosed with BTC and prescribed systemic therapy between January 2011 and September 2020 were retrieved from the Japanese Medical Data Vision database. The look-back period was set to 5 years. Patient characteristics, treatment patterns, and biliary infection-induced treatment interruption were analyzed.The full analysis set comprised 22 742 patients with a mean age of 71.0 years and 61.6% were male. The most common BTC type was extrahepatic cholangiocarcinoma (44.6%). The three most common first-line regimens were S-1 monotherapy (33.0%), gemcitabine+cisplatin (32.5%), and gemcitabine monotherapy (18.7%) over the entire observation period (January 2011-September 2021). Patients who received monotherapies tended to be older. Biliary infection-induced treatment interruption occurred in 29.5% of patients, with a median time to onset of 64.0 (interquartile range 29.0-145.0) days. The median duration of intravenous antibiotics was 12.0 (interquartile range 4.0-92.0) days.RESULTSThe full analysis set comprised 22 742 patients with a mean age of 71.0 years and 61.6% were male. The most common BTC type was extrahepatic cholangiocarcinoma (44.6%). The three most common first-line regimens were S-1 monotherapy (33.0%), gemcitabine+cisplatin (32.5%), and gemcitabine monotherapy (18.7%) over the entire observation period (January 2011-September 2021). Patients who received monotherapies tended to be older. Biliary infection-induced treatment interruption occurred in 29.5% of patients, with a median time to onset of 64.0 (interquartile range 29.0-145.0) days. The median duration of intravenous antibiotics was 12.0 (interquartile range 4.0-92.0) days.These results demonstrated potential challenges of BTC in Japanese clinical practice particularly use of multiple regimens, commonly monotherapies, which are not recommended as first-line treatment, and the management of biliary infections during systemic therapy.CONCLUSIONSThese results demonstrated potential challenges of BTC in Japanese clinical practice particularly use of multiple regimens, commonly monotherapies, which are not recommended as first-line treatment, and the management of biliary infections during systemic therapy. Abstract Purpose To describe the real‐world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of biliary infection in Japan. Methods Patients diagnosed with BTC and prescribed systemic therapy between January 2011 and September 2020 were retrieved from the Japanese Medical Data Vision database. The look‐back period was set to 5 years. Patient characteristics, treatment patterns, and biliary infection‐induced treatment interruption were analyzed. Results The full analysis set comprised 22 742 patients with a mean age of 71.0 years and 61.6% were male. The most common BTC type was extrahepatic cholangiocarcinoma (44.6%). The three most common first‐line regimens were S‐1 monotherapy (33.0%), gemcitabine+cisplatin (32.5%), and gemcitabine monotherapy (18.7%) over the entire observation period (January 2011–September 2021). Patients who received monotherapies tended to be older. Biliary infection‐induced treatment interruption occurred in 29.5% of patients, with a median time to onset of 64.0 (interquartile range 29.0–145.0) days. The median duration of intravenous antibiotics was 12.0 (interquartile range 4.0–92.0) days. Conclusions These results demonstrated potential challenges of BTC in Japanese clinical practice particularly use of multiple regimens, commonly monotherapies, which are not recommended as first‐line treatment, and the management of biliary infections during systemic therapy. PurposeTo describe the real‐world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of biliary infection in Japan.MethodsPatients diagnosed with BTC and prescribed systemic therapy between January 2011 and September 2020 were retrieved from the Japanese Medical Data Vision database. The look‐back period was set to 5 years. Patient characteristics, treatment patterns, and biliary infection‐induced treatment interruption were analyzed.ResultsThe full analysis set comprised 22 742 patients with a mean age of 71.0 years and 61.6% were male. The most common BTC type was extrahepatic cholangiocarcinoma (44.6%). The three most common first‐line regimens were S‐1 monotherapy (33.0%), gemcitabine+cisplatin (32.5%), and gemcitabine monotherapy (18.7%) over the entire observation period (January 2011–September 2021). Patients who received monotherapies tended to be older. Biliary infection‐induced treatment interruption occurred in 29.5% of patients, with a median time to onset of 64.0 (interquartile range 29.0–145.0) days. The median duration of intravenous antibiotics was 12.0 (interquartile range 4.0–92.0) days.ConclusionsThese results demonstrated potential challenges of BTC in Japanese clinical practice particularly use of multiple regimens, commonly monotherapies, which are not recommended as first‐line treatment, and the management of biliary infections during systemic therapy. |
Author | Ogi, Mizue Horiguchi, Akihiko Ueno, Makoto Tokumaru, Jumpei Hirai, Takehiro Shirakawa, Sachiyo Kitagawa, Hiroshi Hamada, Yoko Shinozaki, Kenta Nishida, Kenichiro |
Author_xml | – sequence: 1 givenname: Makoto surname: Ueno fullname: Ueno, Makoto email: makoto23u@gmail.com organization: Kanagawa Cancer Center – sequence: 2 givenname: Sachiyo surname: Shirakawa fullname: Shirakawa, Sachiyo organization: AstraZeneca K.K – sequence: 3 givenname: Jumpei surname: Tokumaru fullname: Tokumaru, Jumpei organization: AstraZeneca K.K – sequence: 4 givenname: Mizue surname: Ogi fullname: Ogi, Mizue organization: AstraZeneca K.K – sequence: 5 givenname: Kenichiro surname: Nishida fullname: Nishida, Kenichiro organization: AstraZeneca K.K – sequence: 6 givenname: Takehiro surname: Hirai fullname: Hirai, Takehiro organization: AstraZeneca K.K – sequence: 7 givenname: Kenta surname: Shinozaki fullname: Shinozaki, Kenta organization: AstraZeneca K.K – sequence: 8 givenname: Yoko surname: Hamada fullname: Hamada, Yoko organization: AstraZeneca K.K – sequence: 9 givenname: Hiroshi surname: Kitagawa fullname: Kitagawa, Hiroshi organization: AstraZeneca K.K – sequence: 10 givenname: Akihiko surname: Horiguchi fullname: Horiguchi, Akihiko organization: Fujita Health University School of Medicine |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38953871$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc9OGzEQh60K1NDAgRdAlriUQ8Be27GXWxtBIUICofa8mvXOCkf7D9tblFsfoc_YJ8FpgAMSvozl-eaTNb8vZKfrOyTkkLNTzlh2tnooh1MuuflE9riZm9k8N9nO213LCTkIYcXSEVzkgn0mE2FyJYzmeyTeIzT__vx96n1TUfztKuws0r6mYR0its7S6BFii12kgwcbncVA697T0jUO_Dr10yu1kOY8dR1dwgDdOb3HMDYxbFRAK4hQQkAa4lit98luDU3Ag5c6Jb8uL34urmY3tz-uF99uZpbn0syAaayySmVcAs5rIy0qafJKAmO5AqulKSXTtWKlQplpoaXKhAANOsOa52JKvm69g-8fRwyxaF2w2DTQYT-GQjCt0pCc64Qev0NX_ei79LtEGcmlSnCiTraU9X0IHuti8K5NSyg4KzZpFJs0ik0aiT16MY5li9Ub-br7BJxtgSfX4PpjU7G8-n73X_kMEUeWVg |
Cites_doi | 10.1007/s00280-007-0673-7 10.3748/wjg.v29.i19.3027 10.1097/CEJ.0000000000000758 10.1002/jhbp.870 10.1016/S0140-6736(23)00727-4 10.3389/fonc.2022.823705 10.1093/jjco/hyy082 10.1002/jhbp.1219 10.1007/s40801-022-00296-5 10.1016/S0140-6736(21)00153-7 10.1056/EVIDoa2200015 10.1007/s40801-021-00266-3 10.1093/annonc/mdz402 10.1016/j.cmi.2017.02.027 10.3748/wjg.v22.i26.6065 10.1007/s00280-005-0095-3 10.1016/j.currproblcancer.2020.100614 10.1016/j.eclinm.2022.101750 10.1159/000500832 10.1007/s40801-022-00331-5 10.1002/ijc.31144 10.1517/14656566.2012.709234 10.1007/s10096-021-04289-0 10.1016/S0140-6736(22)02038-4 10.1016/j.jtho.2020.03.002 10.1002/cam4.5794 |
ContentType | Journal Article |
Copyright | 2024 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Hepato‐Biliary‐Pancreatic Surgery. 2024 The Authors. Journal of Hepato‐Biliary‐Pancreatic Sciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Hepato‐Biliary‐Pancreatic Surgery. 2024. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2024 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Hepato‐Biliary‐Pancreatic Surgery. – notice: 2024 The Authors. Journal of Hepato‐Biliary‐Pancreatic Sciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Hepato‐Biliary‐Pancreatic Surgery. – notice: 2024. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION K9. 7X8 |
DOI | 10.1002/jhbp.1418 |
DatabaseName | Wiley Online Library Wiley Online Library Free Backfiles Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1868-6982 |
EndPage | 480 |
ExternalDocumentID | 10_1002_jhbp_1418 38953871 JHBP1418 |
Genre | researchArticle Journal Article |
GeographicLocations | Japan |
GeographicLocations_xml | – name: Japan |
GrantInformation_xml | – fundername: AstraZeneca K.K. |
GroupedDBID | --- -5E -5G -BR -Y2 0R~ 0VY 1OC 24P 2JY 2~H 30V 33P 3SF 4.4 52U 52V 53G 5VS 8-1 8TC 8UJ 95. AAESR AAEVG AAHHS AAIAL AANLZ AANXM AAONW AARHV AARTL AASGY AAXRX AAZKR ABCUV ABJNI ABJOX ABQWH ABTEG ABXGK ACAHQ ACBWZ ACBXY ACCFJ ACCZN ACGFS ACGOF ACMXC ACOMO ACPOU ACREN ACXBN ACXQS ADBBV ADBTR ADEOM ADINQ ADIZJ ADKPE ADKYN ADMGS ADOZA ADQRH ADRFC ADXAS ADZMN AEEZP AEGNC AEIGN AEIMD AENEX AEQDE AEUYR AFBBN AFBPY AFEXP AFFPM AFGKR AFLOW AFPWT AFWTZ AGJBK AHBTC AHBYD AHKAY AHMBA AHSBF AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMKLP AMTXH AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BGNMA BHBCM BMXJE BRXPI C45 CSCUP DCZOG DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN EN4 F5P FEDTE FUBAC G-S GODZA GQ6 GQ8 H.X HF~ HGLYW HMJXF HVGLF HZ~ IZIGR JBSCW KBYEO LATKE LEEKS LITHE LOXES LUTES LYRES M4Y MA- MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N2Q NF~ NU0 O66 O9- O93 O9I OVD P2W P9S PQQKQ Q.N QB0 QOS R89 ROL RSV S37 S3B SDE SMD SOJ SUPJJ SV3 SZN TEORI TSV TUC VC2 WBKPD WHWMO WIH WIJ WIK WIN WK8 WOHZO WVDHM WXSBR Z45 Z7U Z82 Z87 Z8V ~EX AAYZH CGR CUY CVF ECM EIF NPM AAYXX CITATION K9. 7X8 |
ID | FETCH-LOGICAL-c1948-a07ed2d5214ae6f84ce5489d4a0095ac748b407f50b5e4273745233a7a72ef193 |
IEDL.DBID | 24P |
ISSN | 1868-6974 1868-6982 |
IngestDate | Fri Jul 26 19:11:28 EDT 2024 Thu Oct 10 22:16:43 EDT 2024 Wed Jul 31 12:42:34 EDT 2024 Sun Oct 13 09:52:30 EDT 2024 Sat Aug 24 00:55:58 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | drug therapy antibiotics chemotherapy cholangiocarcinoma cholangitis |
Language | English |
License | Attribution 2024 The Authors. Journal of Hepato‐Biliary‐Pancreatic Sciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Hepato‐Biliary‐Pancreatic Surgery. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1948-a07ed2d5214ae6f84ce5489d4a0095ac748b407f50b5e4273745233a7a72ef193 |
Notes | Prior publication: Results of this study were presented as an abstract and oral presentation at the 20th Annual Meeting of the Japanese Society of Medical Oncology, 2023. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjhbp.1418 |
PMID | 38953871 |
PQID | 3084145307 |
PQPubID | 2034613 |
PageCount | 13 |
ParticipantIDs | proquest_miscellaneous_3075374467 proquest_journals_3084145307 crossref_primary_10_1002_jhbp_1418 pubmed_primary_38953871 wiley_primary_10_1002_jhbp_1418_JHBP1418 |
PublicationCentury | 2000 |
PublicationDate | July 2024 |
PublicationDateYYYYMMDD | 2024-07-01 |
PublicationDate_xml | – month: 07 year: 2024 text: July 2024 |
PublicationDecade | 2020 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan – name: Tokyo |
PublicationTitle | Journal of hepato-biliary-pancreatic sciences |
PublicationTitleAlternate | J Hepatobiliary Pancreat Sci |
PublicationYear | 2024 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2018; 142 2021; 8 2023; 32 2023; 30 2021; 45 2023; 55 2023; 12 2019; 97 2019; 30 2006; 57 2020; 82 2021; 28 2017; 23 2023; 401 2020; 15 2022; 41 2023. 2012; 13 2018; 48 2022 2023; 29 2022; 9 2022; 12 2021; 397 2022; 1 2008; 62 2016; 22 e_1_2_10_23_1 e_1_2_10_24_1 e_1_2_10_21_1 e_1_2_10_22_1 e_1_2_10_20_1 Maeda O (e_1_2_10_9_1) 2020; 82 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_12_1 e_1_2_10_13_1 e_1_2_10_10_1 e_1_2_10_11_1 e_1_2_10_31_1 e_1_2_10_30_1 e_1_2_10_29_1 e_1_2_10_27_1 e_1_2_10_28_1 e_1_2_10_25_1 e_1_2_10_26_1 |
References_xml | – volume: 397 start-page: 428 year: 2021 end-page: 444 article-title: Biliary tract cancer publication-title: Lancet – volume: 1 year: 2022 article-title: Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer publication-title: NEJM Evidence – volume: 142 start-page: 1671 year: 2018 end-page: 1675 article-title: Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer publication-title: Int J Cancer – volume: 55 year: 2023 article-title: Duration of antibiotic treatment for gram‐negative bacteremia—systematic review and individual participant data (IPD) meta‐analysis publication-title: EClinicalMedicine – volume: 9 start-page: 543 year: 2022 end-page: 550 article-title: A review of research studies using data from the administrative claims databases in Japan publication-title: Drugs Real World Outcomes – volume: 23 start-page: 740 year: 2017 end-page: 747 article-title: Impact of inadequate initial antimicrobial therapy on mortality in patients with bacteraemic cholangitis: a retrospective cohort study publication-title: Clin Microbiol Infect – volume: 29 start-page: 3027 year: 2023 end-page: 3039 article-title: Short vs long‐course antibiotic therapy in adults with acute cholangitis: a systematic review, meta‐analysis, and evidence quality assessment publication-title: World J Gastroenterol – volume: 62 start-page: 849 year: 2008 end-page: 855 article-title: S‐1 monotherapy as first‐line treatment in patients with advanced biliary tract cancer: a multicenter phase II study publication-title: Cancer Chemother Pharmacol – volume: 13 start-page: 1943 year: 2012 end-page: 1959 article-title: S‐1 for the treatment of gastrointestinal cancer publication-title: Expert Opin Pharmacother – volume: 30 start-page: 1950 year: 2019 end-page: 1958 article-title: Combination gemcitabine plus S‐1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA‐BT (JCOG1113) randomized phase III clinical trial publication-title: Ann Oncol – volume: 32 start-page: 2 year: 2023 end-page: 9 article-title: Descriptive epidemiology of biliary tract cancer incidence and geographic variation in Japan publication-title: Eur J Cancer Prev – volume: 82 start-page: 725 year: 2020 end-page: 733 article-title: Chemotherapy for biliary tract cancer: real‐world experience in a single institute publication-title: Nagoya J Med Sci – volume: 45 year: 2021 article-title: Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: a systematic review publication-title: Curr Probl Cancer – volume: 48 start-page: 703 year: 2018 end-page: 711 article-title: New developments in systemic therapy for advanced biliary tract cancer publication-title: Jpn J Clin Oncol – volume: 401 start-page: 1853 year: 2023 end-page: 1865 article-title: Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE‐966): a randomised, double‐blind, placebo‐controlled, phase 3 trial publication-title: Lancet – volume: 57 start-page: 647 year: 2006 end-page: 653 article-title: Phase II study of single‐agent gemcitabine in patients with advanced biliary tract cancer publication-title: Cancer Chemother Pharmacol – volume: 30 start-page: 102 year: 2023 end-page: 110 article-title: Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA) publication-title: J Hepatobiliary Pancreat Sci – volume: 9 start-page: 175 year: 2022 end-page: 187 article-title: Context and considerations for use of two Japanese real‐world databases in Japan: medical data vision and Japanese medical data center publication-title: Drugs Real World Outcomes – volume: 22 start-page: 6065 year: 2016 end-page: 6075 article-title: Impact of biliary stent‐related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy publication-title: World J Gastroenterol – volume: 41 start-page: 143 year: 2022 end-page: 146 article-title: Specificities of acute cholangitis in patients with cancer: a retrospective comparative study of 130 episodes publication-title: Eur J Clin Microbiol Infect Dis – volume: 15 start-page: 1147 year: 2020 end-page: 1159 article-title: NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta‐analysis publication-title: J Thorac Oncol – year: 2022 – year: 2023. – volume: 401 start-page: 195 year: 2023 end-page: 203 article-title: Adjuvant S‐1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open‐label, randomised, controlled, phase 3 trial publication-title: Lancet – volume: 28 start-page: 26 year: 2021 end-page: 54 article-title: Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd English edition publication-title: J Hepatobiliary Pancreat Sci – volume: 12 year: 2022 article-title: Effects of concomitant antibiotics use on immune checkpoint inhibitor efficacy in cancer patients publication-title: Front Oncol – volume: 8 start-page: 459 year: 2021 end-page: 480 article-title: Current status, challenges, and future perspectives of real‐world data and real‐world evidence in Japan publication-title: Drugs Real World Outcomes – volume: 12 start-page: 10889 year: 2023 end-page: 10898 article-title: Main causes of death in advanced biliary tract cancer publication-title: Cancer Med – volume: 97 start-page: 191 year: 2019 end-page: 201 article-title: Local therapy in advanced cholangiocarcinoma: a review of current endoscopic, medical, and oncologic treatment options publication-title: Oncology – ident: e_1_2_10_20_1 doi: 10.1007/s00280-007-0673-7 – ident: e_1_2_10_30_1 doi: 10.3748/wjg.v29.i19.3027 – ident: e_1_2_10_15_1 doi: 10.1097/CEJ.0000000000000758 – ident: e_1_2_10_5_1 doi: 10.1002/jhbp.870 – ident: e_1_2_10_2_1 – ident: e_1_2_10_7_1 doi: 10.1016/S0140-6736(23)00727-4 – ident: e_1_2_10_28_1 doi: 10.3389/fonc.2022.823705 – ident: e_1_2_10_4_1 doi: 10.1093/jjco/hyy082 – ident: e_1_2_10_16_1 doi: 10.1002/jhbp.1219 – ident: e_1_2_10_14_1 doi: 10.1007/s40801-022-00296-5 – ident: e_1_2_10_3_1 doi: 10.1016/S0140-6736(21)00153-7 – ident: e_1_2_10_6_1 doi: 10.1056/EVIDoa2200015 – ident: e_1_2_10_13_1 doi: 10.1007/s40801-021-00266-3 – ident: e_1_2_10_17_1 doi: 10.1093/annonc/mdz402 – ident: e_1_2_10_27_1 doi: 10.1016/j.cmi.2017.02.027 – ident: e_1_2_10_24_1 doi: 10.3748/wjg.v22.i26.6065 – ident: e_1_2_10_8_1 – ident: e_1_2_10_21_1 doi: 10.1007/s00280-005-0095-3 – ident: e_1_2_10_19_1 doi: 10.1016/j.currproblcancer.2020.100614 – ident: e_1_2_10_31_1 doi: 10.1016/j.eclinm.2022.101750 – ident: e_1_2_10_10_1 doi: 10.1159/000500832 – ident: e_1_2_10_12_1 doi: 10.1007/s40801-022-00331-5 – ident: e_1_2_10_18_1 doi: 10.1002/ijc.31144 – ident: e_1_2_10_22_1 doi: 10.1517/14656566.2012.709234 – volume: 82 start-page: 725 year: 2020 ident: e_1_2_10_9_1 article-title: Chemotherapy for biliary tract cancer: real‐world experience in a single institute publication-title: Nagoya J Med Sci contributor: fullname: Maeda O – ident: e_1_2_10_26_1 doi: 10.1007/s10096-021-04289-0 – ident: e_1_2_10_25_1 – ident: e_1_2_10_23_1 doi: 10.1016/S0140-6736(22)02038-4 – ident: e_1_2_10_29_1 doi: 10.1016/j.jtho.2020.03.002 – ident: e_1_2_10_11_1 doi: 10.1002/cam4.5794 |
SSID | ssj0000313930 |
Score | 2.4427178 |
Snippet | Purpose
To describe the real‐world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of... To describe the real-world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of biliary... Abstract Purpose To describe the real‐world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management... PurposeTo describe the real‐world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 468 |
SubjectTerms | Aged antibiotics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biliary Tract Neoplasms - drug therapy chemotherapy Cholangiocarcinoma cholangitis Cisplatin - administration & dosage Cisplatin - therapeutic use Databases, Factual Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Drug Combinations drug therapy Female Gemcitabine Humans Infections Japan Male Middle Aged Oxonic Acid - administration & dosage Oxonic Acid - therapeutic use Practice Patterns, Physicians' - statistics & numerical data Retrospective Studies Tegafur - administration & dosage Tegafur - therapeutic use |
Title | Real‐world evidence of systemic treatment practices for biliary tract cancer in Japan: Results of a database study |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjhbp.1418 https://www.ncbi.nlm.nih.gov/pubmed/38953871 https://www.proquest.com/docview/3084145307 https://www.proquest.com/docview/3075374467/abstract/ |
Volume | 31 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NSsNAEB5qe_Eiin_VWlbx4CU0STfZRE-tWErBUoqF3sJussGKpKVp7z6Cz-iTOJM_KSJ4C9lJlszs7Hyzmf0W4JY7GmGAFRkhRnODY0g2lOoqQ3RdpUTkC0fQBufnsTuc8dHcmdfgodwLk_NDVAtu5BnZfE0OLlXa-SENfXtVK_Rzy9uDBsIaj4a0zSfVAguREvrZWSPECG-4CJxLZiHT7lRP78ajXyBzF7NmQWdwCAcFWmS93LxHUNPJMWymCO6-Pj4zslOmi2NB2TJmOS3zImRV-Tgrd0GlDNEpo0pY_GJsx7ssJIuv2SJhIwyZyT2b6nT7vknpVZJR7SjFOJYx0J7AbPD08jg0isMTjNDyuWdIU-jIjjA6c6nd2OOhxuTEj7gkVCVDwT2FyVzsmArNhSBGcMxJu1JIYesYYd0p1JNlos-BmZ6OpIpl5KJk6PhKEKufiBC6-OTyTbgpVRisco6MIGdDtgPSc0B6bkKrVG5QuEkadE2PW9zBeaYJ11UzDnD6ayETvdySDGZUArNWlDnLjVL1gmgLJ2xhNeEus9Lf3QejYX9CFxf_F72EfRshTF6c24L6Zr3VVwhBNqqdDbU2NHqDfn_8DVQR2LQ |
link.rule.ids | 315,786,790,11589,27955,27956,46085,46509 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NSsNAEB5qPehFFP-qVVfx4CU0STfZRLyoWGptSykt9BZ2kw1WJC39ufsIPqNP4kzSRIoI3kJ2kiUzOzvfbGa_BbjmjkYYYEVGiNHc4BiSDaXqyhB1VykR-cIRtMG503WbQ94aOaMS3OV7YTJ-iGLBjTwjna_JwWlBuvbDGvr2qqbo6Ja3AZuciOCI15n3ihUWYiX008NGiBLecBE559RCpl0rnl4PSL9Q5jpoTaNOYxd2VnCR3Wf23YOSTvZh0Ud09_XxmbKdMr06F5RNYpbxMo9DVtSPs3wb1JwhPGVUCoufjO14l4Vk8hkbJ6yFMTO5ZX09X74v5vQqyah4lIIcSyloD2DYeBo8No3V6QlGaPncM6QpdGRHGJ651G7s8VBjduJHXBKskqHgnsJsLnZMhfZCFCM4JqV1KaSwdYy47hDKySTRx8BMT0dSxTJyUTJ0fCWI1k9EiF188vkKXOUqDKYZSUaQ0SHbAek5ID1XoJorN1j5yTyomx63uIMTTQUui2Yc4fTbQiZ6siQZTKkEpq0oc5QZpegF4RbO2MKqwE1qpb-7D1rNhx5dnPxf9AK2moNOO2g_d19OYdtGPJNV6lahvJgt9RnikYU6T4fdNzIy2qA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LS8NAEB5qBfEiiq9q1VU8eAlN0k020ZOvUuuDIhZ6C7vZDVYkLX3c_Qn-Rn-JM0kTKSJ4C9lJlszs7Hyzmf0W4JR7BmGAo60Yo7nFMSRbSjWVJZq-UkKHwhO0wfnxyW_3eKfv9StwUeyFyfkhygU38oxsviYHH-mk8UMa-vaqRujnTrAEy9xH5EC0zrxbLrAQKWGYnTVCjPCWj8C5YBay3Ub59GI8-gUyFzFrFnRa67A2R4vsMjfvBlRMugnTZwR3Xx-fGdkpM_NjQdkwYTkt8yBmZfk4K3ZBTRiiU0aVsPjF2I53WUwWH7NByjoYMtNz9mwms_fphF4lGdWOUoxjGQPtFvRaty_XbWt-eIIVOyEPLGkLo12N0ZlL4ycBjw0mJ6HmklCVjAUPFCZziWcrNBeCGMExJ21KIYVrEoR121BNh6nZBWYHRkuVSO2jZOyFShCrn9AIXUJy-RqcFCqMRjlHRpSzIbsR6TkiPdegXig3mrvJJGraAXe4h_NMDY7LZhzg9NdCpmY4IxnMqARmrSizkxul7AXRFk7YwqnBWWalv7uPOu2rLl3s_V_0CFa6N63o4e7pfh9WXUQzeZ1uHarT8cwcIBqZqsNs1H0D9vvZyQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real%E2%80%90world+evidence+of+systemic+treatment+practices+for+biliary+tract+cancer+in+Japan%3A+Results+of+a+database+study&rft.jtitle=Journal+of+hepato-biliary-pancreatic+sciences&rft.au=Ueno%2C+Makoto&rft.au=Shirakawa%2C+Sachiyo&rft.au=Tokumaru%2C+Jumpei&rft.au=Ogi%2C+Mizue&rft.date=2024-07-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1868-6974&rft.eissn=1868-6982&rft.volume=31&rft.issue=7&rft.spage=468&rft.epage=480&rft_id=info:doi/10.1002%2Fjhbp.1418&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1868-6974&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1868-6974&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1868-6974&client=summon |